SLC5A2 and type 2 diabetes mellitus: Despite the conclusive benefits of SGLT2 inhibitors in patients with T2DM and HF, their efficacy and risk-benefits profile in older individuals and those with frailty remain a matter of ongoing debate and have not been systematically investigated.